DK1442024T3 - Aminobenzamidderivater som glycogensystasekinase 3 beta-inhibitorer - Google Patents
Aminobenzamidderivater som glycogensystasekinase 3 beta-inhibitorerInfo
- Publication number
- DK1442024T3 DK1442024T3 DK02802307T DK02802307T DK1442024T3 DK 1442024 T3 DK1442024 T3 DK 1442024T3 DK 02802307 T DK02802307 T DK 02802307T DK 02802307 T DK02802307 T DK 02802307T DK 1442024 T3 DK1442024 T3 DK 1442024T3
- Authority
- DK
- Denmark
- Prior art keywords
- glycogen synthase
- synthase kinase
- beta inhibitors
- aminobenzamide derivatives
- aminobenzamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Indole Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01204192 | 2001-11-01 | ||
PCT/EP2002/012079 WO2003037877A1 (en) | 2001-11-01 | 2002-10-29 | AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3β INHIBITORS |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1442024T3 true DK1442024T3 (da) | 2008-06-30 |
Family
ID=8181175
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK02802307T DK1442024T3 (da) | 2001-11-01 | 2002-10-29 | Aminobenzamidderivater som glycogensystasekinase 3 beta-inhibitorer |
Country Status (21)
Country | Link |
---|---|
US (1) | US20060063789A1 (zh) |
EP (1) | EP1442024B1 (zh) |
JP (1) | JP2005507420A (zh) |
KR (1) | KR20040062557A (zh) |
CN (1) | CN100436427C (zh) |
AT (1) | ATE389638T1 (zh) |
AU (1) | AU2002363177B2 (zh) |
BR (1) | BR0213790A (zh) |
CA (1) | CA2463823A1 (zh) |
DE (1) | DE60225709T2 (zh) |
DK (1) | DK1442024T3 (zh) |
EA (1) | EA007063B1 (zh) |
ES (1) | ES2303565T3 (zh) |
HU (1) | HUP0402245A3 (zh) |
IL (1) | IL161663A0 (zh) |
MX (1) | MXPA04004176A (zh) |
NO (1) | NO326889B1 (zh) |
NZ (1) | NZ531854A (zh) |
PL (1) | PL368920A1 (zh) |
PT (1) | PT1442024E (zh) |
WO (1) | WO2003037877A1 (zh) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003078448A1 (en) | 2002-03-13 | 2003-09-25 | Signum Biosciences, Inc. | Modulation of protein methylation and phosphoprotein phosphate |
JP2006508997A (ja) * | 2002-11-28 | 2006-03-16 | シエーリング アクチエンゲゼルシャフト | Chk−、Pdk−およびAkt−阻害性ピリミジン、それらの製造および薬剤としての使用 |
DE10322911A1 (de) * | 2003-05-21 | 2004-12-16 | Bayer Materialscience Ag | Verfestigungsstabile blockierte Polyisocyanate |
PL1660458T3 (pl) * | 2003-08-15 | 2012-07-31 | Novartis Ag | 2,4-pirymidynodwuaminy stosowane w leczeniu chorób nowotworowych, chorób zapalnych i zaburzeń układu immunologicznego |
US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
US7923041B2 (en) | 2005-02-03 | 2011-04-12 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
CA2601777A1 (en) * | 2005-02-03 | 2006-08-10 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
EP1885454A2 (en) | 2005-05-04 | 2008-02-13 | DeveloGen Aktiengesellschaft | Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders |
EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
EP2275096A3 (en) | 2005-08-26 | 2011-07-13 | Braincells, Inc. | Neurogenesis via modulation of the muscarinic receptors |
WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
JP2009536669A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス,インコーポレイティド | アンジオテンシン調節による神経新生 |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
MX2009004426A (es) | 2006-10-23 | 2009-08-12 | Cephalon Inc | Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores alk y c-met. |
TW200902010A (en) | 2007-01-26 | 2009-01-16 | Smithkline Beecham Corp | Anthranilamide inhibitors of aurora kinase |
CA2689989A1 (en) | 2007-06-04 | 2008-12-11 | Avila Therapeutics, Inc. | Heterocyclic compounds and uses thereof |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
TWI552752B (zh) * | 2007-10-19 | 2016-10-11 | 賽基艾維洛米斯研究股份有限公司 | 雜芳基化合物及其用途 |
US7989465B2 (en) | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
WO2009071535A1 (en) * | 2007-12-03 | 2009-06-11 | Boehringer Ingelheim International Gmbh | Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation |
US9486441B2 (en) | 2008-04-21 | 2016-11-08 | Signum Biosciences, Inc. | Compounds, compositions and methods for making the same |
JP2011528375A (ja) | 2008-07-16 | 2011-11-17 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト |
WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
US9334269B2 (en) * | 2010-02-17 | 2016-05-10 | Amgen Inc. | Carboxamides as inhibitors of voltage-gated sodium channels |
WO2011144742A1 (en) | 2010-05-21 | 2011-11-24 | Chemilia Ab | Novel pyrimidine derivatives |
US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
KR101938684B1 (ko) | 2011-02-18 | 2019-01-16 | 아사나 바이오사이언시스 엘엘씨 | 아미노인단 화합물 및 통증 치료에서 그것의 용도 |
DK2688883T3 (en) | 2011-03-24 | 2016-09-05 | Noviga Res Ab | pyrimidine |
WO2014028675A1 (en) | 2012-08-15 | 2014-02-20 | Endo Pharmaceuticals Inc. | Use of aminoindane compounds in treating overactive bladder and interstitial cystitis |
WO2014031784A1 (en) | 2012-08-23 | 2014-02-27 | Alios Biopharma, Inc. | Compounds for the treatment of paramoxyvirus viral infections |
CN105764916B (zh) | 2013-06-05 | 2021-05-18 | 博士医疗爱尔兰有限公司 | 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法 |
UA118278C2 (uk) | 2014-01-10 | 2018-12-26 | Глаксосмітклайн Інтеллектьюел Проперті (№ 2) Лімітед | Гідроксиформамідні похідні та їх застосування |
WO2017156527A1 (en) * | 2016-03-11 | 2017-09-14 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Aurora kinase and janus kinase inhibitors for prevention of graft versus host disease |
CN106632021A (zh) * | 2016-09-27 | 2017-05-10 | 中国药科大学 | 2‑取代异烟酸类化合物、其制备方法及其用途 |
EP3920885A1 (en) | 2019-02-08 | 2021-12-15 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
CN112876420B (zh) * | 2019-11-29 | 2023-01-24 | 沈阳化工研究院有限公司 | 一种硫代苯甲酰衍生物及其应用 |
WO2021155185A1 (en) * | 2020-01-30 | 2021-08-05 | Sumitomo Dainippon Pharma Oncology, Inc. | Aminopyrimidinylaminobenzonitrile derivatives as nek2 inhibitors |
CN114105887B (zh) * | 2021-09-16 | 2023-12-01 | 沈阳药科大学 | 一种氨基嘧啶衍生物及其制备方法和用途 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0164204A1 (en) * | 1984-05-12 | 1985-12-11 | FISONS plc | Novel pharmaceutically useful pyrimidines |
EP0162204A3 (de) * | 1984-05-22 | 1988-07-06 | Franz Grimme Landmaschinenfabrik GmbH & Co. KG. | Riemenschloss für Riemen von Siebkettenförderbändern |
ES2087056T3 (es) * | 1986-01-13 | 1996-07-16 | American Cyanamid Co | 2-pirimidinaminas sustituidas en las posiciones 4, 5 y 6. |
US4966622A (en) * | 1988-04-12 | 1990-10-30 | Ciba-Geigy Corporation | N-phenyl-N-pyrimidin-2-ylureas |
GB9012592D0 (en) * | 1990-06-06 | 1990-07-25 | Smithkline Beecham Intercredit | Compounds |
US5516775A (en) * | 1992-08-31 | 1996-05-14 | Ciba-Geigy Corporation | Further use of pyrimidine derivatives |
GB9705361D0 (en) * | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
CN1214014C (zh) * | 1998-03-27 | 2005-08-10 | 詹森药业有限公司 | 抑制hiv的嘧啶衍生物 |
ATE274510T1 (de) * | 1998-06-19 | 2004-09-15 | Chiron Corp | Glycogen synthase kinase 3 inhibitoren |
GB9914258D0 (en) * | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
GB0004890D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
ES2324981T3 (es) * | 2000-12-21 | 2009-08-21 | Smithkline Beecham Corporation | Pirimidinaminas como moduladores de la angiogenesis. |
US20030139435A1 (en) * | 2001-06-26 | 2003-07-24 | Gulzar Ahmed | N-heterocyclic inhibitors of TNF-alpha expression |
US6939874B2 (en) * | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
ATE407678T1 (de) * | 2001-10-17 | 2008-09-15 | Boehringer Ingelheim Pharma | Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung |
-
2002
- 2002-10-29 AU AU2002363177A patent/AU2002363177B2/en not_active Ceased
- 2002-10-29 ES ES02802307T patent/ES2303565T3/es not_active Expired - Lifetime
- 2002-10-29 IL IL16166302A patent/IL161663A0/xx unknown
- 2002-10-29 EP EP02802307A patent/EP1442024B1/en not_active Expired - Lifetime
- 2002-10-29 EA EA200400616A patent/EA007063B1/ru not_active IP Right Cessation
- 2002-10-29 DE DE60225709T patent/DE60225709T2/de not_active Expired - Lifetime
- 2002-10-29 US US10/493,446 patent/US20060063789A1/en not_active Abandoned
- 2002-10-29 HU HU0402245A patent/HUP0402245A3/hu unknown
- 2002-10-29 KR KR10-2004-7004829A patent/KR20040062557A/ko active IP Right Grant
- 2002-10-29 PL PL02368920A patent/PL368920A1/xx not_active Application Discontinuation
- 2002-10-29 CA CA002463823A patent/CA2463823A1/en not_active Abandoned
- 2002-10-29 NZ NZ531854A patent/NZ531854A/xx not_active IP Right Cessation
- 2002-10-29 JP JP2003540159A patent/JP2005507420A/ja active Pending
- 2002-10-29 BR BR0213790-9A patent/BR0213790A/pt not_active IP Right Cessation
- 2002-10-29 CN CNB028219163A patent/CN100436427C/zh not_active Expired - Fee Related
- 2002-10-29 WO PCT/EP2002/012079 patent/WO2003037877A1/en active IP Right Grant
- 2002-10-29 PT PT02802307T patent/PT1442024E/pt unknown
- 2002-10-29 DK DK02802307T patent/DK1442024T3/da active
- 2002-10-29 AT AT02802307T patent/ATE389638T1/de active
- 2002-10-29 MX MXPA04004176A patent/MXPA04004176A/es active IP Right Grant
-
2004
- 2004-06-01 NO NO20042253A patent/NO326889B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE60225709T2 (de) | 2009-05-07 |
US20060063789A1 (en) | 2006-03-23 |
NO20042253L (no) | 2004-06-01 |
NO326889B1 (no) | 2009-03-16 |
CN1703405A (zh) | 2005-11-30 |
EP1442024B1 (en) | 2008-03-19 |
ATE389638T1 (de) | 2008-04-15 |
JP2005507420A (ja) | 2005-03-17 |
NZ531854A (en) | 2006-03-31 |
HUP0402245A3 (en) | 2010-03-29 |
AU2002363177B2 (en) | 2008-09-18 |
EP1442024A1 (en) | 2004-08-04 |
CN100436427C (zh) | 2008-11-26 |
WO2003037877A1 (en) | 2003-05-08 |
MXPA04004176A (es) | 2004-09-06 |
HUP0402245A2 (hu) | 2005-02-28 |
KR20040062557A (ko) | 2004-07-07 |
EA200400616A1 (ru) | 2004-08-26 |
BR0213790A (pt) | 2004-12-07 |
PL368920A1 (en) | 2005-04-04 |
PT1442024E (pt) | 2008-06-12 |
EA007063B1 (ru) | 2006-06-30 |
DE60225709D1 (de) | 2008-04-30 |
IL161663A0 (en) | 2004-09-27 |
ES2303565T3 (es) | 2008-08-16 |
CA2463823A1 (en) | 2003-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1442024T3 (da) | Aminobenzamidderivater som glycogensystasekinase 3 beta-inhibitorer | |
CY1106132T1 (el) | Παραγωγα πιπepιδινης ως αναστολεις καναλιου καλιου | |
DK1483265T3 (da) | Purinderivater som kinaseinhibitorer | |
GB0100889D0 (en) | Compounds | |
IL163777A0 (en) | Kinase inhibitors | |
WO2001019828A3 (en) | Kinase inhibitors as therapeutic agents | |
ATE420879T1 (de) | Indolizine als kinaseproteinhemmer | |
ATE491703T1 (de) | Phthalazinonderivate | |
WO2002074726A3 (en) | Aniline derivatives useful as phosphodiesterase 4 inhibitors | |
PL361404A1 (en) | Synergistic combinations comprising a renin inhibitor for cardiovascular diseases | |
CY1107634T1 (el) | Φαρμακευτικη συνθεση | |
ATE400567T1 (de) | Kinaseinhibitoren | |
CY1106247T1 (el) | Θειοφαινο- και θειαζολοσουλφοναμιδες ως αντινεοπλαστικοι παραγοντες | |
MY141255A (en) | Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs | |
DE60135919D1 (de) | Farnesyl transferase-hemmende 6-heterocyclylmethyl-chinolin und chinazol-derivate | |
NO20061317L (no) | Imidazopyridinderivater som induserbare NO-syntaseinhibatorer | |
MY143516A (en) | Kinase inhibitors | |
DK1246809T3 (da) | 5-aryl-1H-1,2,4-triazolforbindelser som inhibitor for cyclooxygenase-2 og farmaceutiske sammensætninger som indeholder dem | |
EA200801145A1 (ru) | Спироциклические производные хиназолина в качестве ингибиторов pde7 | |
EA200801200A1 (ru) | ПРОИЗВОДНЫЕ ПИРАЗОЛИЗОХИНОЛИНМОЧЕВИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ p38 КИНАЗЫ | |
SE0103710D0 (sv) | Compounds | |
NO20050871L (no) | 6-amino-1H-indazol- og 4-aminobenzofuranforbindelser som fosfodiesterase 4-inhibitorer | |
NO20061344L (no) | Imidazopyridinderivater som induserbare NO-syntaseoinhibitorer | |
NO20061316L (no) | Imidazopyndinderivater som induserbare NO-syntaseinhibitorer | |
AP2002002466A0 (en) | 3-heterocycliylpropanohydroxamic acid PCP INHIBITORS. |